Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TxCell Granted Five New Patents in Major Global Territories

Published: Wednesday, August 27, 2014
Last Updated: Wednesday, August 27, 2014
Bookmark and Share
Latest US patent key to TxCell’s innovative personalized cellular therapy business model.

TxCell SA has announced that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014.

These five new patents cover an important part of TxCell’s core technology and ASTrIA platform. These patents strengthen TxCell’s intellectual property positioning and competitive advantage.

The most recent patent, US 881553, has been granted in the USA on August 26 2014. This patent is for the TxCell method of assessing the efficacy of an antigen-specific Type 1 Treg cell therapy in a patient. The patent is a key asset for the company as it forms an important part of TxCell’s innovative business model.

The ability to use this method to determine responder from non-responder patients after the first administration of TxCell’s cellular immunotherapies would further increase the value of TxCell technologies and as a result, provide a powerful tool in future discussions with payers. TxCell will use this method during the forthcoming phase IIb clinical study with the company’s lead product Ovasave® in severe refractory Crohn’s disease patients.

The patent JP 5502322 granted in Japan describes a method for the isolation of a food- or auto-antigen specific Type 1 Treg cell population. This Japanese patent is, as well, of strategic importance for TxCell as it protects the first step of the TxCell proprietary manufacturing process for making unique personalized cellular immunotherapies.

The further patents granted are respectively for use of antigen specific Type 1 Treg cell populations for treating multiple sclerosis, granted in China, and for the use of pharmaceutical compositions comprising Type 1 Treg cells and mesenchymal stem cells in combination, granted in Japan and Australia.

"TxCell has dedicated years of effort in research and development to establish a robust intellectual property portfolio. This patent coverage will be critical for our ongoing efforts to make cellular immunotherapies available to the large number of patients with a variety of conditions with unmet medical need that are waiting for innovative therapeutic options," said Damian Marron, Chief Executive Officer of TxCell. “We believe these valuable new patents are an essential addition to our patent collection. TxCell now owns or controls a total of more than 140 granted patents in the field of antigen-specific Treg cell-based therapy, with dozens of additional patents pending. These will provide the company with very strong protection for its ASTrIA platform and portfolio of cellular immunotherapy treatments. We will continue to actively patent new discoveries to further protect and extend our innovative technology and products.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
TxCell to Present at the Cell & Gene Therapy Forum 2015
Company to present its experience with Cell Therapy at the Cell & Gene Therapy Forum 2015, Washington.
Saturday, January 24, 2015
TxCell to Lead POSITIVE Project to Automate First Production Step of Ovasave®
Grant of over EUR 400,000 awarded by the Conseil Régional Provence-Alpes-Côte-D’azur to the consortium of TxCell, Gene and Cell therapy Unit, Nice (UTCG) and Biosafe.
Saturday, July 05, 2014
TxCell Granted Certificate of GMP Compliance for Cell Therapy Manufacturing Facility
Confirmation of quality of TxCell’s manufacturing platform by ANSM enables regulatory submissions for Ovasave® phase IIb clinical study.
Friday, June 13, 2014
TxCell Obtains Manufacturing Accreditation Status
Company receives accreditation from ANSM for its French cell therapy manufacturing facility.
Wednesday, December 04, 2013
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!